UBS Group’s Sucampo Pharmaceuticals SCMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
– Sell
-263,403
Closed -$4.73M – 8517
2017
Q4
$4.73M Buy
263,403
+224,460
+576% +$2.76M ﹤0.01% 2405
2017
Q3
$460K Buy
38,943
+12,619
+48% +$142K ﹤0.01% 4274
2017
Q2
$276K Sell
26,324
-4,445
-14% -$45.3K ﹤0.01% 4540
2017
Q1
$339K Sell
30,769
-21,847
-42% -$254K ﹤0.01% 4303
2016
Q4
$713K Buy
52,616
+22,749
+76% +$317K ﹤0.01% 3851
2016
Q3
$368K Buy
29,867
+25,900
+653% +$305K ﹤0.01% 4127
2016
Q2
$44K Buy
3,967
+2,351
+145% +$26.3K ﹤0.01% 5620
2016
Q1
$18K Sell
1,616
-1,294
-44% -$16.4K ﹤0.01% 6303
2015
Q4
$50K Sell
2,910
-10,756
-79% -$193K ﹤0.01% 5825
2015
Q3
$271K Buy
13,666
+12,750
+1,392% +$292K ﹤0.01% 4396
2015
Q2
$15K Hold
916
– – ﹤0.01% 7148
2015
Q1
$14K Buy
916
+280
+44% +$4.34K ﹤0.01% 7387
2014
Q4
$9K Sell
636
-3,235
-84% -$34.2K ﹤0.01% 8524
2014
Q3
$26K Buy
3,871
+2,777
+254% +$18.4K ﹤0.01% 7678
2014
Q2
$8K Buy
+1,094
New +$7.74K ﹤0.01% 9148

Other funds holding SCMP

UBS Group's SCMP Position: Q1 2018 in Review

UBS Group sold out of Sucampo Pharmaceuticals (SCMP) in Q1 2018, closing a stake of 263,403 shares — an estimated $4.73M sold.

UBS Group first reported a position in SCMP in Q2 2014 and held it in 15 quarters. The position peaked at $4.73M in Q4 2017. 2 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • UBS Group reported no remaining Sucampo Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • UBS Group sold 263,403 Sucampo Pharmaceuticals shares in Q1 2018, an estimated $4.73M.
  • UBS Group first reported a position in Sucampo Pharmaceuticals in Q2 2014 and held it in 15 quarters.
  • UBS Group's Sucampo Pharmaceuticals position peaked at $4.73M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals as of Q1 2018.

Based on UBS Group's 13F filing for Q1 2018, filed 15 May 2018.